Lipids, lifestyle and prevention

14:00–14:10

Welcome, introduction and workshop objectives

Chairpersons

14:10–15:00  SESSION 1 - Residual risk with lipid-lowering therapy: what is the scope of the problem?

14:10–14:20

What are the key insights from registries/real-world studies?

Prof. Kausik Ray, London

14:20–14:30

How can imaging be utilized to characterize residual risk?

Dr. Victoria Delgado, Leiden

14:30–15:00

Discussion

15:00–16:00  SESSION 2 – Addressing residual risk beyond statin therapy: what is the current landscape for add-on/combination therapy?

15:00–15:10

Strategies targeting PCSK9 (MoAb, siRNA)

Prof. Wouter Jukema, Leiden

15:10–15:20

Strategies targeting ACL

Prof. Ulrich Laufs, Leipzig

15:20–15:30

How IPE can potentially address residual risk in patients on statins/other therapies

Prof. Jose-Luis Zamorano, Madrid

15:30–16:00

Discussion

16:30–17:00  SESSION 3 – What is the role of heart healthy diets?

16:30–16:40

Mediterranean diet: lessons from PREDIMED

Prof. Emilio Ros, Barcelona

16:40–16:50

Role of phytosterols and fiber

Prof. Jogchum Plat, Maastricht

16:50–17:00

Discussion

17:00-17:30  LECTURE 
What are the insights into targeting inflammation to reduce residual risk with lipid-lowering therapies?

Prof. Peter Libby, Boston via Zoom

17:30-18:00

Panel discussion

17:30  END OF DAY 1

09:30–09:45

Summary of Day 1  

Chairpersons

09:45–10:30  SESSION 5 – Patient perspective on lipid-lowering therapy

09:45–10:30

Patient perspective

Dr Akos Gesztes, Hungary

10:30–11:00  SESSION 6 – Addressing residual risk beyond statin therapy: How is the evolving landscape for strategies targeting non-LDL Cholesterol (Lp(a), ApoCIII, ANGPTL3)?

10:30–10:50

Overview

Prof. Lale Tokgozoglu, Ankara

10:50–11:05

Focus on anti-Lp(a) as target of therapy

Prof. Chris Packard, Glasgow

11:05–11:30

Panel Discussion

11:30–11:45

Wrap-up, summary and next steps for a publication

Chairpersons

End of the workshop